|
 AstraZeneca in June picked Emergent to help produce 300 million
doses of its potential COVID-19 vaccine pledged to the United
States.
AstraZeneca has signed manufacturing deals globally to meet its
target of making 2 billion doses of the vaccine, including with two
Bill Gates-backed ventures and a $1.2 billion agreement with the
U.S. government.
The company's vaccine, which has been co-developed by University of
Oxford, is among the first to move into mid-stage trials. There are
no approved vaccines or treatments for COVID-19, the highly
contagious respiratory illness caused by the novel coronavirus.
[to top of second column] |
The latest contract follows an $87 million contract in June where Emergent
signed an agreement to become the development partner for AstraZeneca's COVID-19
vaccine candidate.
Activities under the agreement will be at Emergent's Baltimore Bayview facility,
the company said, which is a designated center by the U.S. Department of Health
and Human Services for rapid manufacturing of large quantities of vaccines and
treatments.
(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli and Shounak
Dasgupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
